Clinical characteristics of human parvovirus B19 infection after allogeneic stem cell transplantation
10.3760/cma.j.cn121090-20231128-00284
- VernacularTitle:异基因造血干细胞移植后人细小病毒B19感染24例临床分析
- Author:
Jin ZHANG
1
;
Rui MA
;
Xueyi LUO
;
Xiaohui ZHANG
;
Lanping XU
;
Yu WANG
;
Xiaodong MO
;
Meng LYU
;
Kaiyan LIU
;
Xiaojun HUANG
;
Yuqian SUN
Author Information
1. 北京大学人民医院、北京大学血液病研究所、国家血液系统疾病临床医学研究中心，造血干细胞移植治疗血液病北京市重点实验室，北京 100044
- From:
Chinese Journal of Hematology
2024;45(6):591-593
- CountryChina
- Language:Chinese
-
Abstract:
Human parvovirus B19 (HPVB19) belongs to Parvoviridae, a genus of erythrovirus, and has been associated with various human diseases, and HPVB19 infection is one of the most important causes of refractory anemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study retrospectively analyzed 24 patients with HSCT combined with HPVB19 infection to collate and summarize the clinical presentation, treatment, and regression of patients with combined HPVB19 infection after allo-HSCT and provide experience in the management of HPVB19 infection after allo-HSCT. The median age of the patients with HPVB19 infection was 25 years, and the median time of infection occurrence was +107 days after transplantation, and 22 (91.7% ) had anemia with a median hemoglobin (HGB) level of 77.5 (46-149) g/L, and 13 (54.2% ) had new-onset anemia or persistent decline in HGB. The median length of hospital stay was 19 days. Among patients with new-onset anemia or persistent decline in HGB, the mean increase in HGB after treatment with intravenous immunoglobulin and/or antiviral therapy was 15.69 g/L, and treatment was effective in 10 (76.92% ) patients. HPVB19 infection should be alerted to the development of refractory anemia after HSCT; despite the lack of specific treatment, the overall prognosis of HPVB19-infected patients is good.
